Published in
Springer Nature [academic journals on nature.com], British Journal of Cancer, 6(115), p. 649-654, 2016
DOI: 10.1038/bjc.2016.222
Links
- Springer Nature [academic journals on nature.com] | PDF
- [hdl.handle.net]
- [www.ncbi.nlm.nih.gov] | PDF
- [www.research.manchester.ac.uk] | PDF
- [europepmc.org] | PDF
Tools
FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience.
Journal article published in 2016 by
Muralidharan K. Chllamma,
Natalie Cook,
Neesha C. Dhani,
Kazim Giby,
Anna Dodd,
Lisa Wang,
David W. Hedley,
Malcolm J. Moore,
Jennifer J. Knox
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 
Abstract
FOLFIRINOX has been shown to significantly increase both overall survival (OS) and progression-free survival (PFS) in metastatic pancreas cancer. There is limited data regarding the treatment of locally advanced pancreatic cancer. We present a retrospective study of patients with both locally advanced and metastatic pancreas cancer using FOLFIRINOX as first-line therapy in our centre.